Sender Company & Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Sender Company & Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,556	Closed	-$88.2K	–	110
2025 Q4	$88.2K	Sell	21,556 -4,493	-17%	-$22.3K	0.04%	100
2025 Q3	$127K	Buy	26,049 +2,226	+9%	+$11.7K	0.01%	436
2025 Q2	$121K	Buy	+23,823	New	+$117K	0.03%	262
2024 Q2	–	Sell	-12,934	Closed	-$129K	–	49
2024 Q1	$129K	Buy	+12,934	New	+$144K	0.22%	32

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sender Company & Partners's RXRX Position: Q1 2026 in Review

Sender Company & Partners sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 21,556 shares — an estimated $88.2K sold.

Sender Company & Partners first reported a position in RXRX in Q1 2024 and held it in 4 quarters. The position peaked at $129K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Sender Company & Partners reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sender Company & Partners sold 21,556 Recursion Pharmaceuticals shares in Q1 2026, an estimated $88.2K.
Sender Company & Partners first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Sender Company & Partners's Recursion Pharmaceuticals position peaked at $129K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Sender Company & Partners's 13F filing for Q1 2026, filed 15 May 2026.